Sunovion Pharmaceuticals Inc. Announces Nationwide Availability of ZETONNA™ (ciclesonide) Nasal Aerosol for Allergic Rhinitis

Published: Jul 30, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced the nationwide availability of ZETONNA™ (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older. It is the only dry nasal aerosol approved by the U.S. Food and Drug Administration (FDA) with once daily, one spray per nostril (37 mcg) dosing.

Back to news